| Name | Title | Contact Details |
|---|
Pulse Staffing is the largest provider of medical personnel in the Southeast Texas area. We have over eighteen years experience staffing the facilities of the Texas Medical Center, the largest collection of hospitals in the world. Our reputation for
Sarstedt Group is a Newton, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Onyx is an ISO certified and FDA approved vendor for nearly all of the world's largest orthopedic companies. Founded in 1990, we specialize in making a complete line of wires, guide pins, half pins, drills and screws, utilizing the latest in
What`s best for each patient drives our business. Through Center for Diagnostic Imaging`s national network, including Insight Imaging, we partner with healthcare providers to do what we do best — manage and deliver high-quality medical imaging (i.e. MRI, PET/CT, etc.) and related services (i.e. injections for pain) to enhance patient care. CDI offers the highest quality of care through a network of outpatient imaging centers and mobile facilities in more than thirty states. Headquartered in Minneapolis, Minnesota; the organization serves more than one million patients a year through a diverse set of customers including healthcare providers, managed care organizations, hospitals, health systems and payors (government and third party). Our local providers and partners are connected through CDI`s large network to other clinical providers and staff across the country. Through CDI`s sophisticated network, our partners access best practices and have the ability to consult with other specialized physicians, when needed, to improve patient care and outcomes. Being a national provider that is locally focused helps CDI provide each patient with the best of both worlds: individualized local patient care and extensive healthcare expertise.
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.